Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference in New York City from September 17-19, 2024. The company's management team will:
- Host one-on-one meetings with investors
- Participate in a fireside chat and Q&A session on Tuesday, September 17th, at 3:05 PM EDT
A live webcast of the session will be available on the Investor section of Aurinia's website. This conference provides an opportunity for Aurinia to engage with investors and showcase its developments in the healthcare sector.
Aurinia Pharmaceuticals (NASDAQ: AUPH) ha annunciato la sua partecipazione al 2024 Cantor Fitzgerald Global Healthcare Conference a New York City dal 17 al 19 settembre 2024. Il team di gestione dell'azienda:
- Condurrà incontri individuali con gli investitori
- Parteciperà a una chiacchierata informale e a una sessione di domande e risposte martedì 17 settembre alle 15:05 EDT
Un webcast dal vivo della sessione sarà disponibile nella sezione Investor del sito web di Aurinia. Questa conferenza offre un'opportunità per Aurinia di interagire con gli investitori e mostrare i suoi sviluppi nel settore sanitario.
Aurinia Pharmaceuticals (NASDAQ: AUPH) anunció su participación en la 2024 Cantor Fitzgerald Global Healthcare Conference en la ciudad de Nueva York del 17 al 19 de septiembre de 2024. El equipo de gestión de la compañía:
- Realizará reuniones individuales con inversores
- Participará en una conversación informal y en una sesión de preguntas y respuestas el martes 17 de septiembre a las 3:05 PM EDT
Una transmisión web en vivo de la sesión estará disponible en la sección de Inversores del sitio web de Aurinia. Esta conferencia brinda una oportunidad para que Aurinia se relacione con los inversores y muestre sus desarrollos en el sector de la salud.
Aurinia Pharmaceuticals (NASDAQ: AUPH)는 2024년 9월 17일부터 19일까지 뉴욕시에서 열리는 2024 Cantor Fitzgerald Global Healthcare Conference에 참가한다고 발표했습니다. 회사의 경영진은:
- 투자자와의 일대일 미팅을 진행합니다
- 9월 17일 화요일 오후 3시 5분 EDT에 진행되는 대화 및 Q&A 세션에 참여합니다
세션의 라이브 웹캐스트는 Aurinia의 웹사이트 투자자 섹션에서 이용할 수 있습니다. 이 회의는 Aurinia가 투자자와 소통하고 건강 관리 분야의 발전을 선보일 수 있는 기회를 제공합니다.
Aurinia Pharmaceuticals (NASDAQ: AUPH) a annoncé sa participation à la 2024 Cantor Fitzgerald Global Healthcare Conference à New York du 17 au 19 septembre 2024. L'équipe de direction de l'entreprise :
- Organisera des réunions individuelles avec les investisseurs
- Participera à une discussion informelle et à une session de questions-réponses le mardi 17 septembre à 15h05 EDT
Un webinaire en direct de la session sera disponible dans la section Investisseur du site Web d'Aurinia. Cette conférence offre une occasion à Aurinia de dialoguer avec les investisseurs et de mettre en avant ses développements dans le secteur de la santé.
Aurinia Pharmaceuticals (NASDAQ: AUPH) hat seine Teilnahme an der 2024 Cantor Fitzgerald Global Healthcare Conference in New York City vom 17. bis 19. September 2024 bekannt gegeben. Das Management-Team des Unternehmens wird:
- Einzelgespräche mit Investoren führen
- An einem informellen Gespräch und einer Fragerunde am Dienstag, den 17. September, um 15:05 Uhr EDT teilnehmen
Ein Live-Webcast der Sitzung wird im Investor-Bereich der Aurinia-Website verfügbar sein. Diese Konferenz bietet Aurinia die Möglichkeit, mit Investoren in Kontakt zu treten und ihre Entwicklungen im Gesundheitssektor vorzustellen.
- None.
- None.
Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 17th, at 3:05 PM EDT. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found here.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240913634435/en/
Media & Investor Inquiries:
Andrea Christopher
Corporate Communications & Investor Relations
Aurinia Pharmaceuticals Inc.
achristopher@auriniapharma.com
General Investor Inquiries:
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
FAQ
When is Aurinia Pharmaceuticals (AUPH) participating in the Cantor Fitzgerald Global Healthcare Conference?
What activities will Aurinia Pharmaceuticals (AUPH) management engage in during the 2024 Cantor Fitzgerald conference?
How can investors watch Aurinia Pharmaceuticals' (AUPH) presentation at the 2024 Cantor Fitzgerald conference?
What is the significance of Aurinia Pharmaceuticals (AUPH) attending the 2024 Cantor Fitzgerald Global Healthcare Conference?
